C4 Therapeutics Inc
NASDAQ:CCCC

Watchlist Manager
C4 Therapeutics Inc Logo
C4 Therapeutics Inc
NASDAQ:CCCC
Watchlist
Price: 4.93 USD -3.9%
Market Cap: 341.8m USD
Have any thoughts about
C4 Therapeutics Inc?
Write Note

Intrinsic Value

CCCC's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one CCCC stock under the Base Case scenario is 1.99 USD. Compared to the current market price of 4.93 USD, C4 Therapeutics Inc is Overvalued by 60%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CCCC Intrinsic Value
1.99 USD
Overvaluation 60%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
C4 Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CCCC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CCCC?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about C4 Therapeutics Inc

Provide an overview of the primary business activities
of C4 Therapeutics Inc.

What unique competitive advantages
does C4 Therapeutics Inc hold over its rivals?

What risks and challenges
does C4 Therapeutics Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for C4 Therapeutics Inc.

Provide P/S
for C4 Therapeutics Inc.

Provide P/E
for C4 Therapeutics Inc.

Provide P/OCF
for C4 Therapeutics Inc.

Provide P/FCFE
for C4 Therapeutics Inc.

Provide P/B
for C4 Therapeutics Inc.

Provide EV/S
for C4 Therapeutics Inc.

Provide EV/GP
for C4 Therapeutics Inc.

Provide EV/EBITDA
for C4 Therapeutics Inc.

Provide EV/EBIT
for C4 Therapeutics Inc.

Provide EV/OCF
for C4 Therapeutics Inc.

Provide EV/FCFF
for C4 Therapeutics Inc.

Provide EV/IC
for C4 Therapeutics Inc.

Show me price targets
for C4 Therapeutics Inc made by professional analysts.

What are the Revenue projections
for C4 Therapeutics Inc?

How accurate were the past Revenue estimates
for C4 Therapeutics Inc?

What are the Net Income projections
for C4 Therapeutics Inc?

How accurate were the past Net Income estimates
for C4 Therapeutics Inc?

What are the EPS projections
for C4 Therapeutics Inc?

How accurate were the past EPS estimates
for C4 Therapeutics Inc?

What are the EBIT projections
for C4 Therapeutics Inc?

How accurate were the past EBIT estimates
for C4 Therapeutics Inc?

Compare the revenue forecasts
for C4 Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of C4 Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of C4 Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of C4 Therapeutics Inc compared to its peers.

Compare the P/E ratios
of C4 Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing C4 Therapeutics Inc with its peers.

Analyze the financial leverage
of C4 Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for C4 Therapeutics Inc.

Provide ROE
for C4 Therapeutics Inc.

Provide ROA
for C4 Therapeutics Inc.

Provide ROIC
for C4 Therapeutics Inc.

Provide ROCE
for C4 Therapeutics Inc.

Provide Gross Margin
for C4 Therapeutics Inc.

Provide Operating Margin
for C4 Therapeutics Inc.

Provide Net Margin
for C4 Therapeutics Inc.

Provide FCF Margin
for C4 Therapeutics Inc.

Show all solvency ratios
for C4 Therapeutics Inc.

Provide D/E Ratio
for C4 Therapeutics Inc.

Provide D/A Ratio
for C4 Therapeutics Inc.

Provide Interest Coverage Ratio
for C4 Therapeutics Inc.

Provide Altman Z-Score Ratio
for C4 Therapeutics Inc.

Provide Quick Ratio
for C4 Therapeutics Inc.

Provide Current Ratio
for C4 Therapeutics Inc.

Provide Cash Ratio
for C4 Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for C4 Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for C4 Therapeutics Inc?

What is the current Free Cash Flow
of C4 Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for C4 Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
C4 Therapeutics Inc

Current Assets 273.2m
Cash & Short-Term Investments 255.6m
Receivables 10.3m
Other Current Assets 7.2m
Non-Current Assets 102.8m
Long-Term Investments 28.8m
PP&E 65.4m
Other Non-Current Assets 8.7m
Current Liabilities 43.3m
Accounts Payable 1.5m
Accrued Liabilities 19.2m
Other Current Liabilities 22.6m
Non-Current Liabilities 90.1m
Other Non-Current Liabilities 90.1m
Efficiency

Earnings Waterfall
C4 Therapeutics Inc

Revenue
33.7m USD
Operating Expenses
-150.6m USD
Operating Income
-116.9m USD
Other Expenses
11.4m USD
Net Income
-105.5m USD

Free Cash Flow Analysis
C4 Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CCCC Profitability Score
Profitability Due Diligence

C4 Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Exceptional 1-Year Revenue Growth
Negative 3-Years Revenue Growth
Negative Revenue Growth Forecast
21/100
Profitability
Score

C4 Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

CCCC Solvency Score
Solvency Due Diligence

C4 Therapeutics Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
58/100
Solvency
Score

C4 Therapeutics Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CCCC Price Targets Summary
C4 Therapeutics Inc

Wall Street analysts forecast CCCC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CCCC is 16.47 USD with a low forecast of 8.08 USD and a high forecast of 40.95 USD.

Lowest
Price Target
8.08 USD
64% Upside
Average
Price Target
16.47 USD
234% Upside
Highest
Price Target
40.95 USD
731% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CCCC?

Click here to dive deeper.

Dividends

C4 Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CCCC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

C4 Therapeutics Inc Logo
C4 Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

347.5m USD

Dividend Yield

0%

Description

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 121 full-time employees. The company went IPO on 2020-10-02. The firm is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The firm provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The firm is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.

Contact

MASSACHUSETTS
Watertown
490 Arsenal Way, Suite 200
+16172310700.0
c4therapeutics.com

IPO

2020-10-02

Employees

121

Officers

CEO, President & Director
Mr. Andrew J. Hirsch M.B.A.
Co-Founder, Independent Director & Member of Scientific Advisory Board
Dr. Kenneth C. Anderson M.D., Ph.D.
Senior Manager of Investor Relations
Courtney Solberg
Chief Legal Officer & Corporate Secretary
Ms. Jolie M. Siegel J.D.
Chief People Officer
Ms. Kelly A. Schick
Senior Vice President of Strategic Alliances & Business Development
Dr. Isabel Chiu Ph.D.
Show More
Senior Vice President of Chemistry
Dr. Christopher Nasveschuk
Senior Vice President of Biological Sciences
Mr. Roy Pollock Ph.D.
Senior Vice President of Technical Operations, Quality & Facilities
Ms. Mayra Reyes-Armour Ph.D.
Chief Business Officer
Mr. Scott N. Boyle M.B.A., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one CCCC stock?

The intrinsic value of one CCCC stock under the Base Case scenario is 1.99 USD.

Is CCCC stock undervalued or overvalued?

Compared to the current market price of 4.93 USD, C4 Therapeutics Inc is Overvalued by 60%.

Back to Top